Citations

Showing 10 of 108048 citations.

Orthopnea Secondary to Brachial Plexitis with Bilateral Diaphragmatic Paralysis
Labban, Mohamad El , Bauer, Philippe R.

Mayo Clinic

No container title available | November 29, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3635073/v1 Get It

Abstract Background: Diaphragmatic paralysis can present with orthopnea. We report a unique presentation of bilateral diaphragmatic paralysis, an uncommon diagnosis secondary to an unusual cause, brachial plexitis. This report thoroughly describes the patient’s presentation, workup, management, and outcome. It also reviews the literature on diaphragmatic paralysis and Parsonage-Turner syndrome. Case presentation: A 50-year-old male patient developed insidious orthopnea associated with left shoulder and neck pain over three months with no associated symptoms. On examination, marked dyspnea was observed when the patient was asked to lie down; breath sounds were present and symmetrical, and the neurological examination was normal. The chest radiograph showed an elevated right hemidiaphragm. Echocardiogram was normal. There was a 63% positional reduction in Forced Vital Capacity and maximal inspiratory and expiratory pressures on pulmonary function testing. The electromyogram was consistent with neuromuscular weakness involving both brachial plexus and diaphragmatic muscle (Parsonage and Turner syndrome). Conclusions: Compared to unilateral, bilateral diaphragmatic paralysis may be more challenging to diagnose. On PFT, reduced maximal respiratory pressures, especially the maximal inspiratory pressure, are suggestive. Parsonage-Turner syndrome is rare, usually with unilateral diaphragmatic paralysis, but bilateral cases have been reported.
Surgeon Sex and Health Care Costs for Patients Undergoing Common Surgical Procedures
Aminoltejari, Khatereh, Kaneshwaran, Kirusanthy , Salles, Arghavan , Buntin, Melinda Beeuwkes, Coburn, Natalie G. , Wright, Frances C. , Conn, Lesley Gotlib , Heybati, Kiyan , Luckenbaugh, Amy N. , Riveros, Carlos , McCartney, Colin J. L. , Bass, Barbara L. , Detsky, Allan S. , Satkunasivam, Raj , Wallis, Christopher J D , Jerath, Angela , Ranganathan, Sanjana , Armstrong, Kathleen

Mayo Clinic

JAMA Surgery | November 29, 2023 | Volume: 159 | Issue: 2 | Pages: 151

10.1001/jamasurg.2023.6031 | PMID 38019486 Get It

ImportancePrior research has shown differences in postoperative outcomes for patients treated by female and male surgeons. It is important to understand, from a health system and payer perspective, whether surgical health care costs differ according to the surgeon’s sex.ObjectiveTo examine the association between surgeon sex and health care costs among patients undergoing surgery.Design, Setting, and ParticipantsThis population-based, retrospective cohort study included adult patients undergoing 1 of 25 common elective or emergent surgical procedures between January 1, 2007, and December 31, 2019, in Ontario, Canada. Analysis was performed from October 2022 to March 2023.ExposureSurgeon sex.Main Outcome and MeasureThe primary outcome was total health care costs assessed 1 year following surgery. Secondarily, total health care costs at 30 and 90 days, as well as specific cost categories, were assessed. Generalized estimating equations were used with procedure-level clustering to compare costs between patients undergoing equivalent surgeries performed by female and male surgeons, with further adjustment for patient-, surgeon-, anesthesiologist-, hospital-, and procedure-level covariates.ResultsAmong 1 165 711 included patients, 151 054 were treated by a female surgeon and 1 014 657 were treated by a male surgeon. Analyzed at the procedure-specific level and accounting for patient-, surgeon-, anesthesiologist-, and hospital-level covariates, 1-year total health care costs were higher for patients treated by male surgeons ($24 882; 95% CI, $20 780-$29 794) than female surgeons ($18 517; 95% CI, $16 080-$21 324) (adjusted absolute difference, $6365; 95% CI, $3491-9238; adjusted relative risk, 1.10; 95% CI, 1.05-1.14). Similar patterns were observed at 30 days (adjusted absolute difference, $3115; 95% CI, $1682-$4548) and 90 days (adjusted absolute difference, $4228; 95% CI, $2255-$6202).Conclusions and RelevanceThis analysis found lower 30-day, 90-day, and 1-year health care costs for patients treated by female surgeons compared with those treated by male surgeons. These data further underscore the importance of creating inclusive policies and environments supportive of women surgeons to improve recruitment and retention of a more diverse and representative workforce.
Cold Versus Hot Endoscopic Mucosal Resection for Sessile Serrated Colorectal Polyps ≥10 mm
Malik, Talia F. , Deliwala, Smit , Kassab, Lena L., Chandan, Saurabh , Sharma, Neil , Chandan, Saurabh , Mohan, Babu P. , Adler, Douglas G.

Mayo Clinic

Journal of Clinical Gastroenterology | November 29, 2023 | Volume: 58 | Issue: 9 | Pages: 889-895

10.1097/mcg.0000000000001951 | PMID 38019045 Get It

Introduction: We performed a systematic review and meta-analysis studying the efficacy and safety of cold versus hot endoscopic mucosal resection (EMR) for resection of sessile serrated polyps (SSPs) ≥10 mm. Methods: Multiple databases were searched until January 2023 for studies reporting outcomes of cold versus hot EMR for SSPs ≥10 mm. The primary outcome was the residual SSP rate. Secondary outcomes included technical success rate, R0 resection rate, and adverse events. We used standard meta-analysis methods using the random-effects model, and I 2% was used to assess heterogeneity. Results: Thirteen studies were included in the final analysis. In all, 1896 SSPs were included with a mean polyp size of 23.7 mm (range, 15.9 to 33). A total of 1452 SSPs were followed up for a median follow-up duration of 15.3 months (range, 6 to 37). The pooled residual SSP rate for cold EMR was 4.5% (95% CI: 1.0-17.4), and 5.1% (95% CI: 2.4-10.4) for hot EMR (P=0.9). The pooled rates of technical success, R0 resection, immediate bleeding, and perforation were comparable. Hot EMR was significantly associated with lower piecemeal resection (59.2% vs. 99.3%, P<0.001), higher en-bloc resection (41.4% vs. 1.4%, P<0.001), and delayed bleeding rate (4% vs. 0.7%, P=0.05) compared to cold EMR. Conclusions: Cold EMR has similar efficacy compared to hot EMR for resection of SSP ≥ 10 mm, despite limitations in piecemeal R0 resection rate reporting. Although hot EMR was associated with a higher rate of en-bloc resection, it also showed an increased risk of delayed bleeding compared to cold EMR.
Symptom Outcomes of Celiac Disease in Those on a Gluten-free Diet
Hujoel, Isabel A. , Choung, Rok Seon , Hujoel, Margaux L.A. , Murray, Joseph A.

Mayo Clinic

Journal of Clinical Gastroenterology | November 29, 2023 | Volume: 58 | Issue: 8 | Pages: 781-788

10.1097/mcg.0000000000001946 | PMID 38019078 Get It

Goals: We aimed to evaluate symptom outcomes in those on a gluten-free diet during the 5 years after diagnosis. Background: Celiac disease is common; however, little is known about long-term symptom outcomes. Study: We performed a retrospective chart review on individuals with celiac disease followed at a tertiary referral center between 2012 and 2018. To minimize bias, strict inclusion/exclusion criteria were utilized. Only those with definitive biopsy-proven celiac disease, on a gluten-free diet, and with systematic follow-up were included. The standardized care at this center reduced the risk that decisions on testing and follow-up visits were determined by symptom status. Summary statistics were computed and generalized linear models with a logit link were used to associate the proportion of symptomatic visits with various covariates using R statistical programming. Results: Of the 1023 records reviewed, 212 met inclusion/exclusion criteria; 146 (69%) were female and the mean age at diagnosis was 43 (range: 11 to 84 y old). During follow-up, over 50% remained symptomatic, with many having the same symptoms that prompted the diagnosis. The only predictors for remaining symptomatic were female sex and younger age at diagnosis. Abnormal serology during follow-up and small bowel normalization were not predictive. Conclusions: In individuals with definitive celiac disease with systematic long-term follow-up in a Celiac Clinic, roughly half remained symptomatic despite a gluten-free diet. Many suffer from the same symptoms that prompted the diagnosis of celiac disease. Small bowel healing and abnormal serology in follow-up were not predictive of remaining symptomatic. These findings stress the importance of long-term care in celiac disease.
Intraoperative Fluorescence Imaging During Robotic Pancreatoduodenectomy to Detect Suture-Induced Hypoperfusion of the Pancreatic Stump as a Predictor of Postoperative Pancreatic Fistula (FLUOPAN): Prospective Proof-of-concept Study
Zwart, M. , Festen, Sebastiaan , Slooter, M. D. , Dijkum, Els J.�M. Nieveen van , HPB-Amsterdam, for, Chen, Jeffrey , Lof, Sanne , Busch, Olivier R , Daams, Freek D. , Fong, Zhi Ven , Hogg, Melissa E. , Besselink, Marc G , HPB-Amsterdam, for

Mayo Clinic

Annals of Surgery Open | November 29, 2023 | Volume: 4 | Issue: 4 | Pages: e354

10.1097/as9.0000000000000354 | PMID 38144496 Get It

Background: A potential downside of robotic pancreatoduodenectomy (RPD) is the lack of tactile feedback when tying sutures, which could be especially perilous during pancreatic anastomosis. Near-infrared fluorescence imaging with indocyanine green (NIRF-ICG) could detect transpancreatic-suture-induced hypoperfusion of the pancreatic stump during RPD, which may be related to postoperative pancreatic fistula (POPF) grade B/C, but studies are lacking. Methods: This prospective study included 37 patients undergoing RPD to assess the relation between pancreatic stump hypoperfusion as objectified with NIRF-ICG using Firefly and the rate of POPF grade B/C. In 27 patients, NIRF-ICG was performed after tying down the transpancreatic U-sutures. In 10 ‘negative control’ patients, NIRF-ICG was performed before tying these sutures. Results: Pancreatic stump hypoperfusion was detected using NIRF-ICG in 9/27 patients (33%) during RPD. Hypoperfusion was associated with POPF grade B/C (67% [6/9 patients] versus 17% [3/18 patients], P = 0.026). No hypoperfusion was objectified in 10 ‘negative controls’. Conclusions: Transpancreatic-suture-induced pancreatic stump hypoperfusion can be detected using NIRF-ICG during RPD and was associated with POPF grade B/C. Surgeons could use NIRF-ICG to adapt their suturing approach during robotic pancreatico-jejunostomy. Further larger prospective studies are needed to validate the association between transpancreatic-suture-induced hypoperfusion and POPF.
BRAT1-Associated Leukodystrophy Exacerbated by Classic Hodgkin Lymphoma–Directed Therapy
Hooshmand, Sara , Chohan, Karan , Renaud, Deborah L. , Ruff, Michael W. , Chohan, Karan L , Hooshmand, Sara J , Raghunathan, Aditya

Mayo Clinic

The Neurologist | November 29, 2023 | Volume: 29 | Issue: 3 | Pages: 170-172

10.1097/nrl.0000000000000539 | PMID 38019165 Get It

Introduction: BRCA1-associated ataxia-telangiectasia–mutated activator-1 (BRAT1) is responsible for cell cycle surveillance and mitochondrial function. The implications of adult-onset BRAT1-variant and the resulting phenotypic neurocognitive and imaging features have not been previously described. Case Report: A 66-year-old man with a recent diagnosis of classic Hodgkin lymphoma was referred to neuro-oncology for cognitive and motor decline, and progressive cerebral white matter changes noted on magnetic resonance imaging (MRI). A neurological examination revealed global weakness, broad-based gait, and bilateral extensor plantar responses. Brain MRI demonstrated periventricular, deep, and subcortical white matter T2/FLAIR hyperintensities without contrast enhancement. Cerebral spinal fluid studies were unremarkable. A GeneDX genetic leukodystrophy panel conduction revealed a pathogenic variant (c.294dupA; p.L99TfsX92) resulting in a truncated protein of BRAT1, along with a variant of uncertain significance (c.746A>G;p.E249G). A presumptive diagnosis of late-onset leukoencephalopathy secondary to the BRAT1 variant was made. In an attempt to combat his mitochondrial dysfunction, he was initiated on a mitochondrial cocktail, including B-100 complex and coenzyme Q10. He began lymphoma-directed combination chemotherapy and developed precipitous functional decline after 2 cycles of therapy. Compared with prechemotherapy imaging, repeat positron emission tomography/computed tomography metabolic imaging showed a response after 3 cycles of chemotherapy; however, repeat brain MRI showed worsening diffuse white matter hyperintensities and cerebral atrophy. Conclusion: Given the variability in phenotypes and clinical onset, leukodystrophies can be a diagnostic challenge. This case demonstrated progressive BRAT1-associated leukodystrophy exacerbated by chemotherapy-induced toxic leukoencephalopathy. Mitochondrial energy deficiency in the context of multiple metabolic insults was likely underlying the progressive neurological decline observed in this case of genetic leukodystrophy.
Mortality and Morbidity of Heart Failure Hospitalization in Adult Patients With Congenital Heart Disease
Agasthi, Pradyumna , Houten, Holly K. Van , Yao, Xiaoxi , Jain, C. Charles , Egbe, Alexander C. , Warnes, Carole A. , Miranda, William R. , Dunlay, Shannon M. , Stephens, Elizabeth H. , Johnson, Jonathan N. , Connolly, Heidi M. , Van Houten, Holly K , Egbe, Alexander C , Burchill, Luke J , Yao, Xiaoxi , Dunlay, Shannon , Burchill, Luke J.

Mayo Clinic

Journal of the American Heart Association | November 29, 2023 | Volume: 12 | Issue: 23 | Pages: No page available

10.1161/jaha.123.030649 | PMID 38018491 Get It

Background Little is known about outcomes following heart failure (HF) hospitalization among adults with congenital heart disease (CHD) in the United States. We aim to compare the outcomes of HF versus non‐HF hospitalizations in adults with CHD. Methods and Results Using a national deidentified administrative claims data set, patients with adult congenital heart disease (ACHD) hospitalized with and without HF (ACHDHF+, ACHDHF−) were characterized to determine the predictors of 90‐day and 1‐year mortality and quantify the risk of mortality, major adverse cardiac and cerebrovascular events, and health resource use. Cox proportional hazard regression was used to compare ACHDHF+ versus ACHDHF− for risk of events and health resource use. Of 26 454 unique ACHD admissions between January 1, 2010 and December 31, 2020, 5826 (22%) were ACHDHF+ and 20 628 (78%) were ACHDHF−. The ACHD HF+ hospitalizations increased from 6.6% to 14.0% ( P <0.0001). Over a mean follow‐up period of 2.23 ± 2.19 years, patients with ACHDHF+ had a higher risk of mortality (hazard ratio [HR], 1.86 [95% CI, 1.67–2.07], P <0.001), major adverse cardiac and cerebrovascular events (HR, 1.73 [95% CI, 1.63–1.83], P <0.001) and health resource use including rehospitalization (HR, 1.09 [95% CI, 1.05–1.14], P <0.001) and increased postacute care service use (HR, 1.56 [95% CI, 1.32–1.85], P <0.001). Cardiology clinic visits within 30 days of hospital admission were associated with lower 90‐day and 1‐year all‐cause mortality (odds ratio [OR], 0.62 [95% CI, 0.49–0.78], P <0.001; OR, 0.69 [95% CI, 0.58–0.83], P <0.001, respectively). Conclusions HF hospitalization is associated with increased risk of mortality and morbidity with high health resource use in patients with ACHD. Recent cardiology clinic attendance appears to mitigate these risks.
Techniques for Measurement of Serotonin: Implications in Neuropsychiatric Disorders and Advances in Absolute Value Recording Methods
Cabrera, Juan M. Rojas , Oesterle, Tyler , Rusheen, Aaron E. , Goyal, Abhinav , Scheitler, Kristen M. , Mandybur, Ian, Bennet, Kevin E. , Heien, Michael L. , Jang, Dong Pyo , Lee, Kendall H. , Shin, Hojin , Rojas Cabrera, Juan M , Heien, Michael L , Jang, Dong Pyo , Oh, Yoonbae , Shin, Hojin , Oesterle, Tyler S , Mandybur, Ian, Blaha, Charles D. , Oh, Yoonbae

Mayo Clinic

ACS Chemical Neuroscience | November 29, 2023 | Volume: 14 | Issue: 24 | Pages: 4264-4273

10.1021/acschemneuro.3c00618 | PMID 38019166 Get It

Updated systematic review of the effects of exercise on understudied health outcomes in cancer survivors
Sturgeon, Kathleen M. , Kleckner, Ian R. , McNeil, Jessica , Parry, Traci L. , Hamilton, Andrew D. , Schmitz, Kathryn H. , Campbell, Kristin L. , Parry, Traci L , Ehlers, Diane K. , Schmitz, Kathryn H , Kok, Dieuwertje E. G. , Guertin, Kristin A. , Hamilton, Andrew, Winters‐Stone, Kerri M.

Mayo Clinic

Cancer Medicine | November 29, 2023 | Volume: 12 | Issue: 24 | Pages: 22278-22292

10.1002/cam4.6753 | PMID 38018376 Get It

AbstractIntroductionThe American College of Sports Medicine provided guidelines for exercise prescriptions in cancer survivors for specific cancer‐ and treatment‐related health outcomes. However, there was insufficient evidence to generate exercise prescriptions for 10 health outcomes of cancer treatment. We sought to update the state of evidence.MethodsWe conducted a systematic review of these 10 understudied health outcomes (bone health, sleep, cardiovascular function, chemotherapy‐induced peripheral neuropathy (CIPN), cognitive function, falls and balance, nausea, pain, sexual function, and treatment tolerance) and provided an update of evidence.ResultsWhile the evidence base for each outcome has increased, there remains insufficient evidence to generate exercise prescriptions. Common limitations observed across outcomes included: variability in type and quality of outcome measurement tools, variability in definitions of the health outcomes, a lack of phase III trials, and a majority of trials investigating breast or prostate cancer survivors only.ConclusionWe identified progress in the field of exercise oncology for several understudied cancer‐ and treatment‐related health outcomes. However, we were not able to generate exercise prescriptions due to continued insufficient evidence base. More work is needed to prescribe exercise as medicine for these understudied health outcomes, and our review highlights several strategies to aid in research acceleration within these areas of exercise oncology.
Long‐term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma
Lo, Winifred , Ferrone, Cristina R. , Nebbia, Martina , Pery, Ron, Steel, Jennifer L. , Tohme, Samer , Lo, Winifred M , Cleary, Sean, Dogeas, Epameinondas , Etherington, Mark S. , Cleary, Sean P. , Geller, David A.

Mayo Clinic

Journal of Surgical Oncology | November 29, 2023 | Volume: 129 | Issue: 3 | Pages: 568-573

10.1002/jso.27539 | PMID 38018352 Get It

AbstractBackground and ObjectivesThere is limited research on management of metastatic anal canal squamous cell carcinoma (SCC) to the liver. This study aimed to describe outcomes for patients undergoing liver resection of anal SCC metastases.MethodsA multicenter, retrospective cohort study was conducted by three tertiary‐referral centers. Patients undergoing liver surgery between 2008 and 2022 were included. Cox regression analysis was performed to evaluate predictors of recurrence and survival and Kaplan–Meier analysis was performed for 1‐, 3‐, and 5‐year survival.ResultsTwenty‐one patients underwent liver resection and/or ablation. None were HIV positive and 24% had known HPV infection. 20/21(95%) patients had undergone Nigro protocol for management of the primary tumor with 12/21 (57%) patients experiencing complete response. 4/21 (19%) patients had synchronous liver metastases at time of diagnosis. Median tumor size was 5.0 cm and median tumor number was one. At analysis, 52% remained alive. Median overall survival was 32.2 months. 5‐year overall survival was 50%. Median recurrence‐free survival was 7.7 months and 5‐year recurrence‐free survival was 30%. Need for salvage abdominoperineal resection was negatively associated with recurrence‐free survival. The most common site of recurrence was the liver.ConclusionsLiver resection for metastatic anal SCC can be beneficial for appropriately selected patients.